文献速递临床试验与 GCP

N-ICE试验研究方案:一项关于N-乙酰半胱氨酸(NAC)作为甲基苯丙胺(“冰毒”)依赖药物治疗的安全性与有效性的随机双盲安慰剂对照研究

A study protocol for the N-ICE trial: A randomised double-blind placebo-controlled study of the safety and efficacy of N-acetyl-cysteine (NAC) as a pharmacotherapy for methamphetamine ("ice") dependence.
PubMed 文献 · Trials · 2019-06-04

N-ICE试验是一项在澳大利亚三个门诊中心开展的两臂平行双盲安慰剂对照随机试验(1:1),纳入180例甲基苯丙胺依赖且有意减少使用、未接受物质使用障碍治疗的受试者,比较口服NAC 2400 mg/日与安慰剂带回家服用12周的安全性和有效性,主要结局为12周内甲基苯丙胺使用天数及每周唾液检测阳性。

要点

  • 主要结局为12周内甲基苯丙胺使用天数及每周甲基苯丙胺阳性唾液检测。
  • 该试验是首个评估NAC能否减少甲基苯丙胺使用的临床试验。

核心结论

  • N-ICE试验是首个评估NAC能否减少甲基苯丙胺使用的临床试验,将增进对NAC在管理甲基苯丙胺依赖及临床相关结局中潜在效用的理解。
  • 若发现有效,带回家服用的NAC可能成为一种可扩展且可负担的甲基苯丙胺依赖药物治疗选择。

研究设计与样本

  • 两臂平行双盲安慰剂对照三中心随机试验,按1:1比例采用可变区组大小的置换区组随机化,按中心、性别及甲基苯丙胺是否注射分层。
  • 计划纳入180例受试者(每中心60例),需符合甲基苯丙胺依赖、有意减少使用且目前未接受物质使用障碍治疗。
  • 试验在澳大利亚墨尔本、吉朗和卧龙岗的门诊机构开展。
  • 受试者接受口服NAC 2400 mg或匹配安慰剂,作为带回家药物服用12周,每日早晨自行服用两粒600 mg胶囊、晚间再服用两粒。
  • 依从性通过eCAP™药瓶盖监测,记录每次开瓶的日期和时间。

主要发现

  • 主要结局为12周试验用药期间甲基苯丙胺使用情况,包括(a)使用天数(采用时间线回溯法评估)和(b)每周采集的甲基苯丙胺阳性唾液检测。
  • 次要指标包括每周评估甲基苯丙胺渴求、甲基苯丙胺依赖严重程度、甲基苯丙胺戒断症状及精神症状(抑郁、自杀倾向、精神病性症状和敌意)。
  • 每周评估时监测不良事件,耐受性采用药物治疗满意度问卷评估。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: There are currently no approved pharmacotherapies for managing methamphetamine dependence. N-acetylcysteine (NAC) has been found to reduce the craving for methamphetamine and other drugs, but its effect on methamphetamine use and other clinically related endpoints are uncertain. The N-ICE trial is evaluating the safety and efficacy of NAC as a take-home pharmacotherapy for methamphetamine dependence. METHODS/DESIGN: This is a two-arm parallel double-blind placebo-controlled three-site randomised trial (ratio 1:1) using permuted block randomisation, with variable block sizes. It is stratified by site, sex and whether the methamphetamine is injected or not. Participants (N = 180; 60 per site) need to be dependent on methamphetamine, interested in reducing their methamphetamine use and not currently receiving treatment for substance use disorders. The trial is being conducted in outpatient settings in Melbourne, Geelong and Wollongong, Australia. Participants will receive either 2400 mg oral NAC or a matched placebo, delivered as a take-home medication for 12 weeks. Two 600 mg capsules are self-administered in the morning and two more in the evening. Adherence is being monitored using eCAP™ medication bottle lids, which record the date and time of each occasion the bottle is opened. The primary outcome is methamphetamine use during the 12-week trial medication period, measured as (a) days of use, assessed using the timeline followback, and (b) methamphetamine-positive saliva tests, taken weekly. Secondary measures include weekly assessment of methamphetamine craving, severity of methamphetamine dependence, methamphetamine withdrawal symptoms and psychiatric symptoms (depression, suicidality, psychotic symptoms and hostility). Adverse events are monitored at each weekly assessment. Tolerability is assessed using the Treatment Satisfaction Questionnaire for Medication. DISCUSSION: The N-ICE trial is the first clinical trial to assess whether NAC can reduce methamphetamine use. This trial will improve our understanding of the potential utility of NAC in managing methamphetamine dependence and clinically related outcomes. If found to be effective, take-home NAC could be a potentially scalable and affordable pharmacotherapy option for treating methamphetamine dependence. TRIAL REGISTRATION: Australian and New Zealand Clinical Trials Registry, ACTRN12618000366257 . Registered on 29 May 2018.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. McKetin R, Dean OM, Turner A, et al. A study protocol for the N-ICE trial: A randomised double-blind placebo-controlled study of the safety and efficacy of N-acetyl-cysteine (NAC) as a pharmacotherapy for methamphetamine ("ice") dependence. Trials. 2019. PMID: 31164169. doi:10.1186/s13063-019-3450-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。